

The logo for Meta Health, featuring the words "Meta Health" in a white, sans-serif font. The text is centered between two white, curved lines that form a partial circle around it. Below the logo is a horizontal line that is blue on the left and purple on the right.

Meta Health

META HEALTH PRESENTATION



Disclaimer

This presentation has been prepared and issued by Meta Health Limited (“Meta Health” or the “Company”) to inform interested parties about the Company and its progress. The material contained in this presentation sets out general background information on the Company and its activities. It does not constitute, nor does it contain an offer or invitation to subscribe for or purchase any securities in the Company or an inducement to make an offer or invitation with respect to those securities. No agreement to subscribe for securities in the Company will be entered into on the basis of this presentation. The distribution of this document in jurisdictions outside of Singapore may be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe, all such restrictions.

The information supplied is in summary form and does not purport to be complete. Neither the Company nor its advisers have verified the accuracy or completeness of the information, statements and opinions contained in this presentation. Accordingly, to the maximum extent permitted by law, the Company makes no representation and gives no assurance, guarantee or warranty, express or implied, as to, and takes no responsibility and assumes no liability for, the authenticity, validity, accuracy, suitability or completeness of, or any errors in or omission, from any information, statement or opinion contained in this presentation.

You should not act or refrain from acting in reliance on this presentation material. This overview of the Company does not purport to contain all information that its recipients may require in order to make an informed assessment of the Company’s prospects. You should conduct your own investigation and perform your own analysis in order to satisfy yourself as to the accuracy and completeness of the information, statements and opinions contained in this presentation and when making any investment decision. You should seek professional advice from your stockbroker, solicitor, accountant, financial adviser, tax adviser or other independent professional adviser before deciding whether to invest in the Company. The Company and its advisers disclaim liability for any and all loss or damage which may be incurred by any recipient through the use of, or reliance upon, any information, statement or opinion contained in or omitted from this presentation.

FORWARD-LOOKING STATEMENTS

All statements, other than statements of historical fact, included herein, including without limitation, statements regarding forecast cash flows, future expansion plans and development objectives of the Company are forward-looking statements. The forward-looking statements involve subjective judgment, assumptions and analysis and are subject to significant risks, uncertainties and other factors, many of which are outside the control of, and are unknown to the Company. Accordingly, there can be no assurance that such statements or expectations will prove to be accurate and actual results and future events may differ materially from those anticipated or described in this presentation. Subject to any continuing obligations under applicable law or any relevant listing rules of the SGX, the Company disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements in this document to reflect any change in expectations or any change in events, conditions or circumstances on which any such statement is based.

PAST PERFORMANCE

This presentation includes information regarding the past performance of the Company. Investors should be aware that past performance is not indicative of future performance.

SPONSOR’S STATEMENT

This presentation has been prepared by the Company and its contents have been reviewed by the Company’s sponsor, ZICO Capital Pte. Ltd. (the “Sponsor”), in accordance with Rule 226(2)(b) of the Singapore Exchange Securities Trading Limited (“SGX-ST”) Listing Manual Section B: Rules of Catalyst.

This presentation has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this presentation, including the correctness of any of the statements or opinions made or reports contained in this presentation.

The contact person for the Sponsor is Mr Alex Tan, Chief Executive Officer, ZICO Capital Pte. Ltd. at 77 Robinson Road, #06-03 Robinson 77, Singapore 068896, telephone (65) 6636 4201.

01. Company Overview

02. Healthcare Operations

03. Metal Operations

04. Strategies & Outlook

05. 1H2022 Financials

06. Investment Summary

Agenda



Company Overview

Future Ready Healthcare

META HEALTH

Company Overview

Stock Data

5DX.SI
Stock Code

S\$0.029
Stock Price
(As of 12 August 2022)

97.2%
Free Float
(As of 18 March 2022)

S\$15.4m
Market Cap
(As of 12 August 2022)




Full Year Financial Highlight

Key Highlights (\$m)	2020	2021
Revenue	32.2	43.0
Net (Loss)/Profit to Owners	(2.0)	7.7
Adjusted Net (Loss)/Profit	(2.0)	0.2*
Net Asset Value	15.3	23.0
Net (Debt)/Cash	(1.5)	4.7


Source: Company

*Adjusted for gain on sale of MCE Shanghai and expenses related to acquisition of Gainhealth, investment in healthcare, share based payment expenses and impairment of Thailand assets due to impending closure.


Revenue (\$m)




Adjusted EBITDA (\$m)



2021 Adjusted EBIT (\$m)



2021 NAV (\$m)





■ Metal
■ Healthcare

Healthcare segment started contributing in 2H2021

Business Segments

2 Main Business Segments: Metal and Healthcare



*The Group is in the midst of acquiring the remaining 14.93% stake in Gainhealth

Milestones



Founded by Mr KC Chua under Metal Component Engineering (MCE)

1988



Expanded into Malaysia

Awarded Singapore Top 50 Enterprise

2002

1987



Expanded into China

Awarded Singapore Top 50 Enterprise

1999



Awarded Singapore Top 50 Enterprise

Milestones



Listed on SGX

Awarded Singapore Top 50 Enterprise

2009



Metal operations expanded into Thailand



- Strategic Focus
- Group's name changed to Meta Health
- Appointment of Dr Bernard Ng as Executive Chairman and Group CEO
- *To align with Group's strategic direction and progress in Healthcare*

2021

2003



Transferred to SGX Catalyst under the leadership of Mr KC Chua

2013



Expanded into Healthcare sector with acquisition of 85.07% of GainHealth

2022



Healthcare Operations

To provide smarter care for better outcomes and a wholesome experience


META HEALTH

HEALTHCARE DIGITISATION ONLY IN LAST 10 YEARS GLOBALLY

ASEAN Embracing This Change More Rapidly Post Covid



Traditional Healthcare Model



New Digital Healthcare Model



Paper-based



Physician-centric



Independent




Security



Disruption

New entrants are disrupting the traditional healthcare model by offering digital services




Patient Centric

With increased information & data, patients will play a more active role in clinical decision-making



Integrated

Information exchange across system



Trust


Developing a trust based relationship with their healthcare provider who may or may not be physically present

ONLINE CARE PLATFORM

ASEAN Digital Healthcare Market Expected To Continue Growing Strongly

2021 to 2025 growth trends

ASEAN eHealth per segment (USD Million)



Market Size USD 5.6b (2021)



eHealth Apps
USD 97M



eHealth Devices
USD 1313M




Online Doctor Cons
USD 2462M




Online Pharmacy
USD 1727M

Meta Health Aims To Help Healthcare Professionals Digitalise Their Operations



2022 YTD Healthcare Sales Breakdown



- Primary care
- Pharmacy
- IAAS
- Clinical Nutrition Distribution

Primary Care offering

Physical Clinic Model



1 GP Clinic in Singapore



Healthcare screening

Care at Home Model



Home Care



Telemedicine

Accredited and subsidized with




Pharmacy



New Digital Healthcare Model

B2C – E-Pharmacy
(20% of total Pharmacy Sales)




www.gainhealth.life

Over 300 SKUs listed



Average bill size
grew from SGD 39
to **SGD 55**

>14,000 users as at 4Q2021



Revitalise the traditional Healthcare Model

B2B – Central Pharmacy
(80% of total Pharmacy Sales)



Delivering prescriptions for Telemedicine consults | Regular chronic illness refills



Average bill size about S\$35



20 B2B clients including individual GPs, Telemedicine providers and Homecare Nursing groups



Delivers over **150** prescriptions/day

Clinical Nutrition Distribution

New Digital Healthcare Model – Patient centric healthcare (food for wellness)

*Distribution mainly through **B2B** channels, with over **600 repeat** customers to-date*



Brown Rice

Low caloric brown rice created under Gain Foods for B2B distribution and targeted at the elder market and metabolic diseases



Adult Milk Powder

Plant based adult milk mild powder with required wholesome nutrition for preventive health. Brand developed with German partner, 4heroes

Infrastructure as a Service (IAAS)

*MetaHealth is the exclusive licensee of Medtel's technology for SEA, Hong Kong, Australia and New Zealand



qure.ai

matrica

klinify

accordia
accentuates communication

Digital Service Platform



Covered functions

Telemedicine, Medical IoT, Medical Triage, imaging AI, ERP platform, web-based clinic management system, call center platform with web CRM



Distributed through **PT GDM**
(targeting the Indonesian healthcare institutes)

Sold using a fee
Per use/
subscription



Digital Hospital
Digital Solution for Healthcare Service


PT GDM's trademarked product, identified as a key partner of the Indonesian Tourism Medical Association

Healthcare Institutes



New Digital Healthcare Model

Integrated information exchange and disrupting traditional healthcare service delivery




Metal Operations

To be a World Class Mechanical Manufacturing Solutions
Provider

META HEALTH

One-Stop Mechanical Manufacturing Solutions Provider



6

Manufacturing Facilities



3

Countries where operations are in
(China, Thailand, Malaysia)



>1 billion

Stamped parts produced to date















Services Provided

- Prototype
- Precision Stamping
- Automation
- Machining
- Surface Treatment – Powder Coating
- High Mix Low Volume Production
- High Volume Production
- Mechanical Module Assembly
- Full Production Assembly



One-Stop Mechanical Manufacturing Solutions Provider

Sectors served	Type of products including			
Automotive	<ul style="list-style-type: none"> • Antenna • Seat Structure • Lock Mechanism • Occupant Seat Sensor • Rail Guide Mechanism 			
Consumer Electronics	<ul style="list-style-type: none"> • Microwave oven • Video and audio equipment • Personal appliance 			
Imaging & Printer	<ul style="list-style-type: none"> • High volume personal desk top printer, • AIO (all in one) multi-function printer, engineering, plotter • Large format printers 			
Medical/Industrial/Semiconductor	<ul style="list-style-type: none"> • Industry solar energy storage • Industry solar panel bracket • Industry ATM fabrication • Medical blood tester, cleaning system • Semiconductor automation machine • Semiconductor Automated Testing Equipment (ATE) • Semiconductor Foundries Wafer fabrication machine. 			



Outlook

META HEALTH



The management is looking **to explore new streams of business development opportunities and conduct a strategic review of the Group's existing businesses** to create value for shareholders.

- Dr Bernard Ng -

Executive Chairman and Group CEO of Meta Health

Future Plans

Accelerate revenue and profit growth targets



Healthcare



Acquisition of **profitable complementary business** segments



Increase the service and product offerings of central pharmacy



Increase the product offerings offered under clinical distribution



Customer acquisition for IAAS segment



Metal



Turnaround plan to bring topline revenue and profit for metal operations between 18 and 24 months



1H2022 Financials

META HEALTH

1H2022 Financial Highlights


Results Highlights	1H2022 (S\$ m)	1H2021 (S\$ m)	Change (%)
Revenue	18.69	20.16	-7.3%
Adjusted EBITDA	(0.48)*	0.84	N.M
Net (Loss)/Profit	(2.78)	0.01	N.M
Adjusted Net (Loss)/Profit	(1.37)*	0.01	N.M

N.M – not meaningful


EBITDA = Profit/(Loss) before tax + Depreciation + Amortisation + Finance Costs

*Adjusted for closure costs relating to the shutdown of one of the factories in Thailand, stock-based compensation and professional fees incurred for the investments in the new Healthcare businesses in 1H2022.

Revenue (S\$m)




Adjusted EBITDA (S\$m)




Decline in revenue and reported loss mainly due to metal business which encountered challenges derived from supply chain disruption as a result of geopolitical uncertainty and the COVID-19 lockdown in China

1H2022 Financial Highlights

1H2022 Revenue




■ Healthcare ■ Metd




Healthcare segment grew its revenue in 1H2022 by more than 70% from 2H2021.

Segmental Adjusted EBIT (\$m)



Segmental Revenue (\$m)




1H2022 Financial Highlights

Selected Balance Sheet Items	As at 30 June 2022 (\$m)	As at 31 Dec 2021 (\$m)	Comments
Total Assets	39.1	47.2	
Total Liabilities	18.4	24.2	
Total Equity	20.7	23.0	Net Asset Value = 3.9 cents per share (30 June 2022)
Cash & Bank Balances	4.3	10.3	
Borrowings	(4.6)	(5.6)	
Net Debt or (Cash)/Equity	1.3%	(20.3)%	

Cashflow statement (\$m)	1H2022	1H2021
Net cash (used in)/ generated from operating activities	(1.0)	2.1
Net cash (used in)/ generated from investing activities	(2.9)	6.9
Net cash used in financing activities	(1.9)	(0.2)
Cash & cash equivalents at end of period	4.2	13.0

Net Asset Value (\$m) by Segment




Investment Summary

Below book value with a healthy net gearing

- Net Debt/Equity = 1.3%
- Net Asset Value = S\$20.7m (\$13.3m is attributable to the metal business)

Clinical Nutrition Distribution to tap into the central pharmacy's B2B network for distribution

Distributing to over 600 repeat customers including retailers and F&B outlets, Meta Health's distribution arm has room for further growth as it taps into its central pharmacy's network for cross-selling opportunities



Proxy to the digitalization of healthcare in the region

- Central Pharmacy facilitates the delivery of medicine for likes of clinics and nursing homes to end patients
- Rising user base for E-pharmacy
- Provides platform for medical institutes looking to digitalise their operations under the IAAS segment

Infrastructure-as-a-service (IAAS) segment can be highly scalable and profitable

In collaboration with other vendors including MedTel, Meta Health has successfully launched a comprehensive suite of software solutions to help medical institutes digitalise their operations without incurring heavy CAPEX



Thank You



For Investors and media contact

Loke Chunying/Sheryl Ng /Clarissa Ooi



Email

cy@gem-comm.com

sheryl@gem-comm.com

clarissa@gem-comm.com

